glp-1 therapy meal timing weight loss studies Medications: & Diabetes Guide GLP-1 has changed the conversation

Key Products: Orforglipron (Foundayo), is first oral GLP-1 receptor agonist developed by the company that can be taken at any time of day

Last reviewed: May 31, 2026 Last updated: May 31, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

A.BenoitS.EngJ.WoodsS

While there are typically serious limitations to what changes can be made to the method of operation for drug delivery devices, there may also be an opportunity for competing products to differentiate themselves through access to high-quality patient support materials and moderated forums

Ryan, New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?, Reviews in Endocrine and Metabolic Disorders